{{medical}}
{{DISPLAYTITLE:多巴胺受體D<sub>2</sub>}}
{{Infobox gene}}
'''多巴胺受體D<sub>2</sub>'''（{{lang|en|Dopamine receptor D<sub>2</sub>}}，簡稱'''D2R'''），為[[轉譯|轉譯]]自 ''DRD2'' 基因的一種[[多巴胺|多巴胺]]受體蛋白。D2R最早於1975年為{{tsl|en|Philip Seeman||Philip Seeman}}所發現，並將其命名為「抗精神疾患性多巴胺受體」（''antipsychotic dopamine receptor''）<ref>{{cite journal | vauthors = Madras BK | title = History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia | journal = Journal of the History of the Neurosciences | volume = 22 | issue = 1 | pages = 62–78 | date = 2013 | pmid = 23323533 | doi = 10.1080/0964704X.2012.678199 }}</ref>。D2R為所有[[抗精神病药|抗精神病药物]]的作用標的。

== 功能 ==
D2R屬於一種[[多巴胺受體|多巴胺受體]]，並會與G<sub>i</sub>結合。G<sub>i</sub>為[[G蛋白偶联受体|G蛋白偶联受体]]的一種亞型，會抑制[[腺苷酸环化酶|腺苷酸环化酶]]的活性<ref name="pmid11089973">{{cite journal | vauthors = Usiello A, Baik JH, Rougé-Pont F, Picetti R, Dierich A, LeMeur M, Piazza PV, Borrelli E | title = Distinct functions of the two isoforms of dopamine D2 receptors | journal = Nature | volume = 408 | issue = 6809 | pages = 199–203 | date = Nov 2000 | pmid = 11089973 | doi = 10.1038/35041572 }}</ref>。

在小鼠模式中，{{tsl|en|dentate gyrus|齒狀回}}的{{tsl|en|neuronal calcium sensor-1||neuronal calcium sensor-1}}（NCS-1）會影響D2R在細胞膜的表現量。這項機制會影響[[突触可塑性|突触可塑性]]及記憶形成<ref name="pmid19755107">{{cite journal | vauthors = Saab BJ, Georgiou J, Nath A, Lee FJ, Wang M, Michalon A, Liu F, Mansuy IM, Roder JC | title = NCS-1 in the dentate gyrus promotes exploration, synaptic plasticity, and rapid acquisition of spatial memory | journal = Neuron | volume = 63 | issue = 5 | pages = 643–56 | date = Sep 2009 | pmid = 19755107 | doi = 10.1016/j.neuron.2009.08.014 }}</ref>。

在蒼蠅模式中，多巴胺性神經元上的D2R{{tsl|en|autoreceptor|自體受器}}能避免神經元死亡，進而引發類[[帕金森氏症|帕金森氏症]]的症狀<ref name="pmid23452092">{{cite journal | vauthors = Wiemerslage L, Schultz BJ, Ganguly A, Lee D | title = Selective degeneration of dopaminergic neurons by MPP(+) and its rescue by D2 autoreceptors in Drosophila primary culture | journal = Journal of Neurochemistry | volume = 126 | issue = 4 | pages = 529–40 | date = Aug 2013 | pmid = 23452092 | doi = 10.1111/jnc.12228 }}</ref>。
== 同型體{{anchor|D2sh}} ==

[[選擇性剪接|Alternative splicing]] of this gene results in three transcript variants encoding different {{tsl|en|isoform||isoform}}s.<ref name="entrez">{{cite web| title = Entrez Gene: DRD2 dopamine receptor D2| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=1813| accessdate = | archive-date = 2010-03-07| archive-url = https://web.archive.org/web/20100307185846/http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=1813| dead-url = no}}</ref>

The long form ('''D2Lh''') has the "canonical" sequence and functions as a classic post-[[突触|synaptic]] receptor.<ref name="D2 Long and short">{{cite journal | vauthors = Beaulieu JM, Gainetdinov RR | title = The physiology, signaling, and pharmacology of dopamine receptors | journal = Pharmacological Reviews | volume = 63 | issue = 1 | pages = 182–217 | date = Mar 2011 | pmid = 21303898 | doi = 10.1124/pr.110.002642 }}</ref>The short form ('''D2Sh''') is pre-synaptic and functions as an {{tsl|en|autoreceptor||autoreceptor}} that regulates the levels of dopamine in the synaptic cleft.<ref name="D2 Long and short" />[[激动剂|Agonism]] of D2sh receptors inhibits dopamine release; antagonism increases {{tsl|en|dopaminergic||dopaminergic}} release.<ref name="D2 Long and short" />A third D2(Longer) form differs from the canonical sequence where 270V is replaced by VVQ.<ref name = "uniprot">[[UniProt|UniProt]] {{uniprot|P14416}}</ref>

== 基因組 ==
[[等位基因|等位基因]]變異：
* [[A-241G|A-241G]]
* [[C132T|C132T]]、[[G423A|G423A]]、[[T765C|T765C]]、[[C939T|C939T]]、{{tsl|en|C957T||C957T}}，以及[[G1101A|G1101A]]<ref name="pmid12554675">{{cite journal | vauthors = Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV | title = Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor | journal = Human Molecular Genetics | volume = 12 | issue = 3 | pages = 205–16 | date = Feb 2003 | pmid = 12554675 | doi = 10.1093/hmg/ddg055 }}</ref>
* [[Cys311Ser|Cys311Ser]]
* -141C insertion/deletion<ref name="pmid9097961">{{cite journal | vauthors = Arinami T, Gao M, Hamaguchi H, Toru M | title = A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia | journal = Human Molecular Genetics | volume = 6 | issue = 4 | pages = 577–82 | date = Apr 1997 | pmid = 9097961 | doi = 10.1093/hmg/6.4.577 }}</ref>The polymorphisms have been investigated with respect to association with [[精神分裂症|schizophrenia]].<ref name="pmid15211624">{{cite journal | vauthors = Glatt SJ, Faraone SV, Tsuang MT | title = DRD2 -141C insertion/deletion polymorphism is not associated with schizophrenia: results of a meta-analysis | journal = American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics | volume = 128B | issue = 1 | pages = 21–3 | date = Jul 2004 | pmid = 15211624 | doi = 10.1002/ajmg.b.30007 }}</ref>

Some researchers have previously associated the [[多态性_(生物学)|polymorphism]] Taq 1A ([[rs1800497|rs1800497]]) to the ''DRD2'' gene.
However, the polymorphism resides in [[外显子|exon]] 8 of the ''{{tsl|en|ANKK1||ANKK1}}'' gene.<ref name="pmid18621654">{{cite journal | vauthors = Lucht M, Rosskopf D | title = Comment on "Genetically determined differences in learning from errors" | journal = Science | volume = 321 | issue = 5886 | pages = 200; author reply 200 | date = Jul 2008 | pmid = 18621654 | doi = 10.1126/science.1155372 }}</ref>DRD2 TaqIA polymorphism has been reported to be associated with an increased risk for developing motor
fluctuations but not hallucinations in Parkinson's disease.<ref name="pmid11425949">{{cite journal | vauthors = Wang J, Liu ZL, Chen B | title = Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD | journal = Neurology | volume = 56 | issue = 12 | pages = 1757–9 | date = Jun 2001 | pmid = 11425949 | doi = 10.1212/WNL.56.12.1757 }}</ref><ref name="Wang J, Zhao c, Chen B, Liu Z. 2004">{{cite journal | vauthors = Wang J, Zhao C, Chen B, Liu ZL | title = Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease | journal = Neuroscience Letters | volume = 355 | issue = 3 | pages = 193–6 | date = Jan 2004 | pmid = 14732464 | doi = 10.1016/j.neulet.2003.11.006 }}</ref>

== 配體 ==
Most of the older [[抗精神病药|antipsychotic]] drugs such as [[氯丙嗪|chlorpromazine]] and [[氟哌啶醇|haloperidol]] are antagonists for the dopamine D<sub>2</sub> receptor, but are, in general, very unselective, at best selective only for the "D<sub>2</sub>-like family" receptors and so binding to D<sub>2</sub>, D<sub>3</sub> and D<sub>4</sub>, and often also to many other receptors such as those for [[血清素|serotonin]] and [[組織胺|histamine]], resulting in a range of side-effects and making them poor agents for scientific research. In similar manner, older dopamine agonists used for [[帕金森氏症|Parkinson's disease]] such as [[溴隱亭|bromocriptine]] and {{tsl|en|cabergoline||cabergoline}} are poorly selective for one dopamine receptor over another, and, although most of these agents do act as D<sub>2</sub> agonists, they affect other subtypes as well. Several selective D<sub>2</sub> [[配體_(生物化學)|ligands]] are, however, now available, and this number is likely to increase as further research progresses.

===受體致活劑===
{{div col|colwidth=33em}}
* [[溴隱亭|溴隱亭]]（Bromocriptine）：完全受體致活劑
* {{tsl|en|Cabergoline||Cabergoline}}（Caberl）
* [[N,N-Propyldihydrexidine|N,N-Propyldihydrexidine]]：D<sub>1</sub>/D<sub>5</sub>受體制活劑{{tsl|en|dihydrexidine||dihydrexidine}}的類似物，對節後神經元的D2R親和性比節前神經元的D<sub>2</sub>{{tsl|en|autoreceptor||自體受器}}高。
* {{tsl|en|Piribedil||Piribedil}}：同時也是 D<sub>3</sub> 受體致活劑及{{tsl|en|α2-adrenergic receptor||腎上腺素α<sub>2</sub>受體拮抗劑}}
* {{tsl|en|Pramipexole||Pramipexole}}：同時也是D<sub>3</sub>、D<sub>4</sub>受體致活劑
* {{tsl|en|Quinelorane||Quinelorane}}：affinity for D<sub>2</sub> > D<sub>3</sub>
* {{tsl|en|Quinpirole||Quinpirole}}：同時也是D<sub>3</sub>受體致活劑
* {{tsl|en|Ropinirole||Ropinirole}}：完全受體致活劑
* {{tsl|en|Sumanirole||Sumanirole}}：高選擇性完全受體致活劑
* {{tsl|en|Talipexole||Talipexole}}：對D<sub>2</sub>的親和性高於其他的多巴胺受體，但同時也是腎上腺素α<sub>2</sub>受體制活劑及5-HT<sub>3</sub>受體拮抗劑。
{{Div col end}}

===部分受體致活劑===
{{div col|colwidth=33em}}
* {{tsl|en|Aplindore||Aplindore}}
* [[阿立哌唑|阿立哌唑]]（Aripiprazole，在[[美國|美國]]合法）<ref name="Rxlist - Abilify">{{cite web | url = http://www.rxlist.com/abilify-drug.htm | title = Clinical Pharmacology for Abilify | author =  | authorlink =  | date = 2010-01-21 | work =  | publisher = RxList.com | pages =  | archiveurl = https://web.archive.org/web/20100118213854/http://www.rxlist.com/abilify-drug.htm | archivedate = 2010-01-18 | quote =  | accessdate = 2010-01-21 | dead-url = no }}</ref>
* {{tsl|en|Brexpiprazole||Brexpiprazole}}/{{tsl|en|OPC-34712||OPC-34712}}
* {{tsl|en|Cariprazine||Cariprazine}}
* {{tsl|en|RP5063||RP5063}}
* {{tsl|en|GSK-789,472||GSK-789,472}} – Also D<sub>3</sub> antagonist, with good selectivity over other receptors <ref name="pmid20153647">{{cite journal | vauthors = Holmes IP, Blunt RJ, Lorthioir OE, Blowers SM, Gribble A, Payne AH, Stansfield IG, Wood M, Woollard PM, Reavill C, Howes CM, Micheli F, Di Fabio R, Donati D, Terreni S, Hamprecht D, Arista L, Worby A, Watson SP | title = The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure | journal = Bioorganic & Medicinal Chemistry Letters | volume = 20 | issue = 6 | pages = 2013–6 | date = Mar 2010 | pmid = 20153647 | doi = 10.1016/j.bmcl.2010.01.090 }}</ref>
* [[氯胺酮|氯胺酮]]（Ketamine，同時也為NMDA受體拮抗劑）
* [[D-麦角酸二乙胺|LSD]] – in vitro, LSD was found to be a partial agonist and potentiates dopamine-mediated prolactin secretion in lactotrophs.<ref name="pmid9698051">{{cite journal | vauthors = Giacomelli S, Palmery M, Romanelli L, Cheng CY, Silvestrini B | title = Lysergic acid diethylamide (LSD) is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro | journal = Life Sciences | volume = 63 | issue = 3 | pages = 215–22 | year = 1998 | pmid = 9698051 | doi = 10.1016/S0024-3205(98)00262-8 }}</ref>LSD is also a 5-HT<sub>2A</sub> agonist.
* [[莫达非尼|莫达非尼]]（Modafinil）
* {{tsl|en|Roxindole||Roxindole}} (only at the D<sub>2</sub> autoreceptors)
* {{tsl|en|OSU-6162||OSU-6162}}：亦為5-HT<sub>2A</sub>部分受體致活劑，acts as "dopamine stabilizer"
* {{tsl|en|Salvinorin A||Salvinorin A}}：亦為{{tsl|en|Κ-opioid receptor||κ-鴉片類受體致活劑}}。
{{Div col end}}

===受體拮抗劑===
{{div col|colwidth=33em}}
* {{tsl|en|Atypical antipsychotics||Atypical antipsychotics}}
* {{tsl|en|Desmethoxyfallypride||Desmethoxyfallypride}}
* [[多潘立酮|Domperidone]] – D<sub>2</sub> and D<sub>3</sub> antagonist; does not cross the blood-brain barrier
* {{tsl|en|Eticlopride||Eticlopride}}
* {{tsl|en|Fallypride||Fallypride}}
* [[羟嗪|Hydroxyzine]] (Vistaril, Atarax)
* {{tsl|en|Itopride||Itopride}}
* {{tsl|en|L-741,626||L-741,626}}  – highly selective D<sub>2</sub> antagonist
* C<sup>11</sup> {{tsl|en|Raclopride||Raclopride}} radiolabled – commonly employed in [[正电子发射计算机断层扫描|positron emission tomography]] studies<ref name="pmid15256343">{{cite journal | vauthors = Wang GJ, Volkow ND, Thanos PK, Fowler JS | title = Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review | url = https://archive.org/details/sim_journal-of-addictive-diseases_2004_23_3/page/39 | journal = Journal of Addictive Diseases | volume = 23 | issue = 3 | pages = 39–53 | year = 2004 | pmid = 15256343 | doi = 10.1300/J069v23n03_04 }}</ref>
* {{tsl|en|Typical antipsychotics||Typical antipsychotics}}
* SV 293<ref>{{cite journal | vauthors = Huang R, Griffin SA, Taylor M, Vangveravong S, Mach RH, Dillon GH, Luedtke RR | title = The effect of SV 293, a D2 dopamine receptor-selective antagonist, on D2 receptor-mediated GIRK channel activation and adenylyl cyclase inhibition | journal = Pharmacology | volume = 92 | issue = 1–2 | pages = 84–9 | year = 2013 | pmid = 23942137 | doi = 10.1159/000351971 }}</ref>
*[[育亨宾|Yohimbine]]

;[[#Isoforms|D<sub>2</sub>sh]] selective (presynaptic autoreceptors)
* {{tsl|en|Amisulpride||Amisulpride}} (low doses) 
* {{tsl|en|UH-232||UH-232}}
{{Div col end}}

===異位調控因子===
{{div col|colwidth=33em}}
* [[高半胱氨酸|Homocysteine]] – 負向{{tsl|en|allosteric modulator|異位調控因子}}<ref>{{cite journal | vauthors = Agnati LF, Ferré S, Genedani S, Leo G, Guidolin D, Filaferro M, Carriba P, Casadó V, Lluis C, Franco R, Woods AS, Fuxe K | title = Allosteric modulation of dopamine D2 receptors by homocysteine | journal = Journal of Proteome Research | volume = 5 | issue = 11 | pages = 3077–83 | date = Nov 2006 | pmid = 17081059 | doi = 10.1021/pr0601382 }}</ref>
* [[PAOPA|PAOPA]]<ref>{{cite journal | vauthors = Beyaert MG, Daya RP, Dyck BA, Johnson RL, Mishra RK | title = PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine–sensitized preclinical animal model of schizophrenia | journal = European Neuropsychopharmacology | volume = 23 | issue = 3 | pages = 253–62 | date = Mar 2013 | pmid = 22658400 | doi = 10.1016/j.euroneuro.2012.04.010 }}</ref>
* SB-269,652 <ref name="pmid25108820">{{cite journal | vauthors = Lane JR, Donthamsetti P, Shonberg J, Draper-Joyce CJ, Dentry S, Michino M, Shi L, López L, Scammells PJ, Capuano B, Sexton PM, Javitch JA, Christopoulos A | title = A new mechanism of allostery in a G protein–coupled receptor dimer | journal = Nature Chemical Biology | volume = 10 | issue = 9 | pages = 745–52 | date = Sep 2014 | pmid = 25108820 | doi = 10.1038/nchembio.1593 }}</ref><ref name="pmid25453482">{{cite journal | vauthors = Maggio R, Scarselli M, Capannolo M, Millan MJ | title = Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation | journal = European Neuropsychopharmacology | volume = 25 | issue = 9 | pages = 1470–9 | date = Sep 2015 | pmid = 25453482 | doi = 10.1016/j.euroneuro.2014.09.016 }}</ref><ref>{{cite journal | vauthors = Silvano E, Millan MJ, Mannoury la Cour C, Han Y, Duan L, Griffin SA, Luedtke RR, Aloisi G, Rossi M, Zazzeroni F, Javitch JA, Maggio R | title = The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors | journal = Molecular Pharmacology | volume = 78 | issue = 5 | pages = 925–34 | date = Nov 2010 | pmid = 20702763 | pmc = 2981362 | doi = 10.1124/mol.110.065755 }}</ref>
{{Div col end}}

=== Functionally selective ligands ===
* 參見參考文獻<ref name="pmid24831693">{{cite journal | vauthors = Möller D, Kling RC, Skultety M, Leuner K, Hübner H, Gmeiner P | title = Functionally selective dopamine D₂, D₃ receptor partial agonists | journal = Journal of Medicinal Chemistry | volume = 57 | issue = 11 | pages = 4861–75 | date = Jun 2014 | pmid = 24831693 | doi = 10.1021/jm5004039 }}</ref>。

==Protein–protein interactions==
The dopamine receptor D<sub>2</sub> has been shown to [[蛋白質交互作用|interact]] with {{tsl|en|EPB41L1||EPB41L1}},<ref name="pmid12181426">{{cite journal | vauthors = Binda AV, Kabbani N, Lin R, Levenson R | title = D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N | journal = Molecular Pharmacology | volume = 62 | issue = 3 | pages = 507–13 | date = Sep 2002 | pmid = 12181426 | doi = 10.1124/mol.62.3.507 }}</ref>{{tsl|en|PPP1R9B||PPP1R9B}}<ref name="pmid10391935">{{cite journal | vauthors = Smith FD, Oxford GS, Milgram SL | title = Association of the D2 dopamine receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1-interacting protein | journal = The Journal of Biological Chemistry | volume = 274 | issue = 28 | pages = 19894–900 | date = Jul 1999 | pmid = 10391935 | doi = 10.1074/jbc.274.28.19894 }}</ref>and {{tsl|en|NCS-1||NCS-1}}.<ref name="pmid12351722">{{cite journal | vauthors = Kabbani N, Negyessy L, Lin R, Goldman-Rakic P, Levenson R | title = Interaction with neuronal calcium sensor NCS-1 mediates desensitization of the D2 dopamine receptor | journal = The Journal of Neuroscience | volume = 22 | issue = 19 | pages = 8476–86 | date = Oct 2002 | pmid = 12351722 }}</ref>

===Receptor oligomers===
The D<sub>2</sub> receptor forms {{tsl|en|GPCR oligomer||receptor heterodimers}} ''[[in_vivo|in vivo]]'' (in living animals) with other [[G蛋白偶联受体|G protein-coupled receptors]]; these include:<ref name="DA receptor heterodimers">{{cite journal | vauthors = Beaulieu JM, Espinoza S, Gainetdinov RR | title = Dopamine receptors - IUPHAR Review 13 | journal = British Journal of Pharmacology | volume = 172 | issue = 1 | pages = 1–23 | date = Jan 2015 | pmid = 25671228 | doi = 10.1111/bph.12906 | pmc=4280963}}</ref>
*{{tsl|en|D1–D2 dopamine receptor heteromer||D<sub>1</sub>–D<sub>2</sub> dopamine receptor heteromer}} 
*D<sub>2</sub>–{{tsl|en|Adenosine A2A receptor||adenosine A<sub>2A</sub>}}
*D<sub>2</sub>–{{tsl|en|ghrelin receptor||ghrelin receptor}}
*[[#D2sh|D<sub>2sh</sub>]]–{{tsl|en|TAAR1||TAAR1}}{{#tag:ref|D2sh–TAAR1 is a presynaptic [[蛋白二聚体|heterodimer]] which involves the relocation of TAAR1 from the intracellular space to D2sh at the [[细胞膜|plasma membrane]], increased D2sh agonist [[配體_(生物化學)|binding affinity]], and [[訊息傳遞_(生物)|signal transduction]] through the calcium–[[蛋白激酶C|PKC]]–{{tsl|en|NFAT||NFAT}} pathway and [[G蛋白|G-protein]] independent [[蛋白激酶B|PKB]]–{{tsl|en|GSK3||GSK3}} pathway.<ref name="Miller+Grandy 2016">{{cite journal | vauthors = Grandy DK, Miller GM, Li JX | title = "TAARgeting Addiction"-The Alamo Bears Witness to Another Revolution: An Overview of the Plenary Symposium of the 2015 Behavior, Biology and Chemistry Conference | journal = Drug Alcohol Depend. | volume = 159 | issue = | pages = 9–16 | date = February 2016 | pmid = 26644139 | doi = 10.1016/j.drugalcdep.2015.11.014 | quote = This original observation of TAAR1 and DA D2R interaction has subsequently been confirmed and expanded upon with observations that both receptors can heterodimerize with each other under certain conditions ... Additional DA D2R/TAAR1 interactions with functional consequences are revealed by the results of experiments demonstrating that in addition to the cAMP/PKA pathway (Panas et al., 2012) stimulation of TAAR1-mediated signaling is linked to activation of the Ca++/PKC/NFAT pathway (Panas et al.,2012) and the DA D2R-coupled, G protein-independent AKT/GSK3 signaling pathway (Espinoza et al., 2015; Harmeier et al., 2015), such that concurrent TAAR1 and DA DR2R activation could result in diminished signaling in one pathway (e.g. cAMP/PKA) but retention of signaling through another (e.g., Ca++/PKC/NFA)}}</ref><ref name="TAAR1-D2sh">{{cite journal | vauthors = Harmeier A, Obermueller S, Meyer CA, Revel FG, Buchy D, Chaboz S, Dernick G, Wettstein JG, Iglesias A, Rolink A, Bettler B, Hoener MC | title = Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers | journal = Eur Neuropsychopharmacol | volume = 25 | issue = 11 | pages = 2049–61 | year = 2015 | pmid = 26372541 | doi = 10.1016/j.euroneuro.2015.08.011 | quote =  Interaction of TAAR1 with D2R altered the subcellular localization of TAAR1 and increased D2R agonist binding affinity.}}</ref>|group="note"}}

The D<sub>2</sub> receptor has been shown to form hetorodimers ''[[in_vitro|in vitro]]'' (and possibly ''in vivo'') with {{tsl|en|Dopamine D3 receptor||DRD<sub>3</sub>}},<ref>{{cite journal | vauthors = Maggio R, Millan MJ | title = Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance | journal = Current Opinion in Pharmacology | volume = 10 | issue = 1 | pages = 100–7 | date = Feb 2010 | pmid = 19896900 | doi = 10.1016/j.coph.2009.10.001 }}</ref>{{tsl|en|Dopamine receptor D5||DRD<sub>5</sub>}},<ref>{{cite journal | vauthors = Hasbi A, O'Dowd BF, George SR | title = Heteromerization of dopamine D2 receptors with dopamine D1 or D5 receptors generates intracellular calcium signaling by different mechanisms | journal = Current Opinion in Pharmacology | volume = 10 | issue = 1 | pages = 93–9 | date = Feb 2010 | pmid = 19897420 | pmc = 2818238 | doi = 10.1016/j.coph.2009.09.011 }}</ref>and {{tsl|en|5-HT2A receptor||5-HT<sub>2A</sub>}}.<ref>{{cite journal | vauthors = Albizu L, Holloway T, González-Maeso J, Sealfon SC | title = Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors | journal = Neuropharmacology | volume = 61 | issue = 4 | pages = 770–7 | date = Sep 2011 | pmid = 21645528 | pmc = 3556730 | doi = 10.1016/j.neuropharm.2011.05.023 }}</ref>
==註釋==
{{Reflist|group=note}}

== 參考文獻 ==
{{Reflist|2}}

== 外部連結 ==
* {{MeshName|Receptors,+Dopamine+D2}}
* {{cite web|last=Pappas|first=Stephanie|title=Study: Genes Influence Who Your Friends Are|url=http://www.livescience.com/health/genes-influence-friendships-110117.html|work=Imaginova Corp.|publisher=LiveScience|accessdate=20 January 2011}}

{{NLM content}}
{{G protein-coupled receptors}}
{{Dopaminergics}}

[[Category:G蛋白偶联受体|Category:G蛋白偶联受体]]
[[Category:精神藥理學|Category:精神藥理學]]
[[Category:注意力不足過動症生物學|Category:注意力不足過動症生物學]]
[[Category:多巴胺受体|Category:多巴胺受体]]